Chutes & Ladders—David Meeker takes the helm at KSQ Therapeutics

David Meeker, former head of Genzyme, is leading KSQ Therapeutics as CEO.

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Eric Sagonowsky (email) or Angus Liu (email) and we will feature it here at the end of each week.


With $76M round, KSQ names ex-Genzyme head David Meeker as CEO

 
KSQ Therapeutics
David Meeker
was named CEO.

Using a platform called CRISPRomics to guide drug discovery, KSQ Therapeutics launched this week with a $76 million funding round and high-profile leadership. The company is helmed by David Meeker, M.D., who spent more than 20 years at Genzyme and ultimately led that company before leaving earlier this year. Frank Stegmeier, Ph.D., formerly global head of oncology target discovery at Novartis, is serving as chief scientific officer. The company is preparing to advance toward the clinic with some of its candidates, discovered with a platform that screens all human genes in hundreds of models to highlight drug targets that could have a strong effect on molecularly defined cancer subtypes with minimal toxicity. FierceBiotech story

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

In management revamp, Lilly R&D exec Jan Lundberg is retiring

 

Eli Lilly
Jan Lundberg is retiring as president of Lilly Research Labs.

Eli Lilly CEO David Ricks is making his next shake-up. As part of changes announced this week, R&D executive Jan Lundberg, Ph.D., is set to retire at the end of May 2018 after eight years with the drugmaker. He previously served as AstraZeneca's drug discovery research head for a decade. The company promoted Dan Skovronsky, M.D., Ph.D.,  to president of Lilly Research Labs, Josh Smiley to CFO, and Myles O'Neill to head of manufacturing. Chief Information Officer Aarti Shah, Ph.D., joined the executive committee as a part of the moves. Lilly's management shake-up comes shortly after it announced 3,500 job cuts as it hopes to trim costs and refocus. FiercePharma story


Sanofi promotes Stefan Oelrich to top diabetes and CV post

Sanofi
Stefan Oelrich was promoted to head of diabetes and cardiovascular.

After Peter Guenter stepped down last month to take Almirall's CEO job, French pharma giant Sanofi has tapped Stefan Oelrich with managing the company's global diabetes and cardiovascular business. Oelrich, who had been running the business in North America, is tasked with the tough job of growing a segment that's been hit by competitive pressures as payers pit drugmakers against each other for deep discounts. As a result, Sanofi's diabetes and cardio sales have been a drag on overall growth in recent years. In an interview, he said Sanofi is ready to compete not just on rebating but also on value and "clinical differentiation." FiercePharma story


> Cellectis Chief Medical Officer Loan Hoang-Sayag, M.D., left the company to pursue other opportunities. Release

> Jonca Bull, M.D., was appointed vice president of ophthalmology within global product development at PPD. The CRO also named her president of its consulting group, PPD Consulting. FierceCRO story

> Atlas Genetics named a new CEO in Jeffrey Luber. Release

> Medtech giant Boston Scientific selected Desiree Ralls-Morrison, J.D., as its general counsel. Release

> AMRI named Joseph D. Sangregorio its chief human resources officer. Release

Suggested Articles

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.